Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

K. Sarafoglou; C. N. Barnes; M. Huang; E. A. Imel; I. Madu; D. P. Merke; D. Moriarty; S. Nakhle; R. S. Newfield; M. G. Vogiatzi; R. J. Auchus

doi:10.1210/clinem/dgac224

Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

K. Sarafoglou, C. N. Barnes, M. Huang, E. A. Imel, I. Madu, D. P. Merke, D. Moriarty, S. Nakhle, R. S. Newfield, M. G. Vogiatzi, R. J. Auchus

Pediatric Endocrinology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200 mg QD. The correct dose is 200 mg BID.

Original language	English (US)
Pages (from-to)	E3546
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	107
Issue number	8
DOIs	https://doi.org/10.1210/clinem/dgac224
State	Published - Aug 1 2022

Bibliographical note

Publisher Copyright:
© 2022 Endocrine Society. All rights reserved.

Publisher link

10.1210/clinem/dgac224

Find It

Find It at U of M Libraries

Cite this

Sarafoglou, K., Barnes, C. N., Huang, M., Imel, E. A., Madu, I., Merke, D. P., Moriarty, D., Nakhle, S., Newfield, R. S., Vogiatzi, M. G., & Auchus, R. J. (2022). Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. Journal of Clinical Endocrinology and Metabolism, 107(8), E3546. https://doi.org/10.1210/clinem/dgac224

Sarafoglou, K, Barnes, CN, Huang, M, Imel, EA, Madu, I, Merke, DP, Moriarty, D, Nakhle, S, Newfield, RS, Vogiatzi, MG & Auchus, RJ 2022, 'Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies', Journal of Clinical Endocrinology and Metabolism, vol. 107, no. 8, pp. E3546. https://doi.org/10.1210/clinem/dgac224

@article{cb46c81a437a4263953f2f88d20bd582,

title = "Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies",

abstract = "Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200 mg QD. The correct dose is 200 mg BID.",

author = "K. Sarafoglou and Barnes, {C. N.} and M. Huang and Imel, {E. A.} and I. Madu and Merke, {D. P.} and D. Moriarty and S. Nakhle and Newfield, {R. S.} and Vogiatzi, {M. G.} and Auchus, {R. J.}",

year = "2022",

month = aug,

day = "1",

doi = "10.1210/clinem/dgac224",

language = "English (US)",

volume = "107",

pages = "E3546",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Endocrine Society",

number = "8",

}

TY - JOUR

T1 - Correction to

T2 - Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

AU - Sarafoglou, K.

AU - Barnes, C. N.

AU - Huang, M.

AU - Imel, E. A.

AU - Madu, I.

AU - Merke, D. P.

AU - Moriarty, D.

AU - Nakhle, S.

AU - Newfield, R. S.

AU - Vogiatzi, M. G.

AU - Auchus, R. J.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200 mg QD. The correct dose is 200 mg BID.

AB - Table 2 contained an error in the listed dose. For cohort B, the dose was incorrectly listed as 200 mg QD. The correct dose is 200 mg BID.

UR - http://www.scopus.com/inward/record.url?scp=85134431884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134431884&partnerID=8YFLogxK

U2 - 10.1210/clinem/dgac224

DO - 10.1210/clinem/dgac224

M3 - Comment/debate

C2 - 35522202

AN - SCOPUS:85134431884

SN - 0021-972X

VL - 107

SP - E3546

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 8

ER -

Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this